Contact
At Ferrer we use business to fight for social justice. We are a pharmaceutical company that seeks to do things differently, guided by ethics, sustainability and social commitment.
After more than 65 years of experience, at Ferrer we are focusing our business on pulmonary vascular and interstitial lung diseases and rare neurological diseases.
At Ferrer we aim to use business to fight for social justice, prioritizing people, planet and collective action.
Contact
Hemos recibido tu solicitud y la revisaremos a la mayor brevedad posible. Te responderemos tan pronto como sea posible
Se ha producido un error al enviar tu solicitud. Por favor, inténtalo de nuevo en unos minutos. Si el problema persiste, puedes contactar con nosotros a través del siguiente correo electrónico: contacto@ferrer.com
#CollectiveAction
B Corp: What It Means
Read article
#BusinessFocus
How we are changing knowledge in complex diseases
How we are changing knowledge in complex diseases
#GreatPeople
It's not just a workplace: day-to-day life at Ferrer centres
It's not just a workplace: day-to-day life at Ferrer centres
#GreatPeople
We are different: that's what a person at Ferrer is like
We are different: that's what a person at Ferrer is like
#CollectiveAction
B Corp: What It Means
Read article
#BusinessFocus
How we are changing knowledge in complex diseases
How we are changing knowledge in complex diseases
#GreatPeople
It's not just a workplace: day-to-day life at Ferrer centres
It's not just a workplace: day-to-day life at Ferrer centres
#GreatPeople
We are different: that's what a person at Ferrer is like
We are different: that's what a person at Ferrer is like
We join forces with large companies with the purpose of providing solutions to the challenges of Barcelona
Read new
Ferrer and Prilenia Announce Start of PRECISE-HD Confirmatory Clinical Trial of Pridopidine in Huntington's Disease
Read new
First participant in Europe in the Phase 3 clinical trial "PREVAiLS" with pridopidine, in ALS
Read new
IMPAHCT celebrates its eighth edition by reinforcing the comprehensive approach to rare lung diseases
Read new
Ferrer and Prilenia Announce Inclusion of First Participant in Phase 3 Clinical Trial "PREVAiLS" with Pridopidine, in ALS
Read new